EBITDA: Income before interest, taxes, depreciation and amortization.
Sutro Biopharma, Inc. (STRO) had EBITDA of $-91.54M for the most recently reported fiscal year, ending 2023-12-31.
| Income Statement Financials | |
$153.73M |
|
$-106.79M |
|
-- |
|
$153.73M |
|
$243.01M |
|
$-89.28M |
|
$0.68M |
|
$-88.60M |
|
$-88.60M |
|
$-106.79M |
|
$-106.79M |
|
$-106.79M |
|
$-106.79M |
|
$-89.28M |
|
|
EBITDA |
$-91.54M |
60.16M |
|
60.16M |
|
$-1.78 |
|
$-1.78 |
|
| Balance Sheet Financials | |
$421.54M |
|
$21.94M |
|
$49.19M |
|
$470.74M |
|
$93.75M |
|
-- |
|
$227.34M |
|
$321.09M |
|
$149.65M |
|
$149.65M |
|
$149.65M |
|
61.01M |
|
| Cash Flow Statement Financials | |
$-111.62M |
|
$-3.92M |
|
$137.55M |
|
$48.13M |
|
$70.14M |
|
$22.01M |
|
$24.91M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.50 |
|
-- |
|
-- |
|
-- |
|
0.03 |
|
100.00% |
|
-58.07% |
|
-58.07% |
|
-59.54% |
|
-57.63% |
|
-69.47% |
|
$-115.93M |
|
-- |
|
-- |
|
-- |
|
0.33 |
|
-- |
|
4.26 |
|
85.66 |
|
-71.36% |
|
-71.36% |
|
-22.69% |
|
-71.36% |
|
$2.45 |
|
$-1.93 |
|
$-1.86 |
|